Mahmoud Abd -Elmageed Osman
◽
Ehab Hassan Nashat Allam
◽
Christina Alfonse Anwar
◽
Mohammed Soliman Mahmoud Allam
Abstract
Background
HCC is one of the most common malignancies worldwide and is a major cause of death, because of its high frequency and poor prognosis. It is especially common in Egypt, where it develops on top of cirrhosis secondary to viral hepatitis C and B. Since HCV infection is highly prevalent in Egypt, it accounts to most of the cases of HCC in Egypt. HCV infection is found in a variable proportion in HCC cases in different populations, accounting for 75-90% of cases in Japan, 31-47% in the U.S, 44-76% in Italy, and 60%-75% of HCC cases in Spain.
Objective
To compare between Ledipasvir based regimen and Daclatasvir based regimen as regard incidence of Hepatocellular Carcinoma after successful Therapy for patients with chronic hepatitis C virus infection.
Patients and Methods
Our study was a comparative study including 60 patients divided into 2 groups as follow patients successfully treated with Ledipasvir based regimen (Group A) and patients successfully treated with Daclatasvir based regimen (Group B) from January 2016 to June 2017.
Results
There were no statistically significant difference between the two groups as regard demographic and laboratory data. In comparison between Ledipasvir based regimen and Daclatasvir based regimen as regard incidence of Hepatocellular Carcinoma after successful Therapy for patients with chronic hepatitis C virus infection in the first group there were 3/30 cases of percentage of 10% has developed HCC and in the second group there were 2/30 cases of percentage 6.6% has developed HCC after successful therapy for each group, there were no statistically significant difference between the two groups as regard the incidence of HCC after successful treatment, but generally DAA as Ledipasvir based regimen and daclatasvir based regimen both have low incidence of HCC after successful therapy of HCV infection.
Conclusion
There were several researches to study relation between DAA as treatment for HCV infection and HCC incidence after successful therapy. Our study was done to compare between Ledipasvir based regimen and Daclatasvir based regimen as regard incidence of Hepatocellular Carcinoma after successful Therapy for patients with chronic hepatitis C virus infection.
Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma